These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 9339533)
1. Nuchal translucency measurement and second-trimester biochemical screening for Down's syndrome. Frohlich EP Ultrasound Obstet Gynecol; 1997 Sep; 10(3):221-2. PubMed ID: 9339533 [No Abstract] [Full Text] [Related]
2. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study. Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221 [TBL] [Abstract][Full Text] [Related]
3. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study. Crossley JA; Aitken DA; Cameron AD; McBride E; Connor JM BJOG; 2002 Jun; 109(6):667-76. PubMed ID: 12118646 [TBL] [Abstract][Full Text] [Related]
10. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population. Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187 [TBL] [Abstract][Full Text] [Related]
11. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population. Schuchter K; Hafner E; Stangl G; Ogris E; Philipp K Ultrasound Obstet Gynecol; 2001 Jul; 18(1):23-5. PubMed ID: 11489220 [TBL] [Abstract][Full Text] [Related]
12. The use of nuchal translucency measurement and second trimester biochemical markers in screening for Down's syndrome. Michailidis GD; Spencer K; Economides DL BJOG; 2001 Oct; 108(10):1047-52. PubMed ID: 11702836 [TBL] [Abstract][Full Text] [Related]
13. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome. Kadir RA; Economides DL Ultrasound Obstet Gynecol; 1997 Apr; 9(4):244-7. PubMed ID: 9168574 [TBL] [Abstract][Full Text] [Related]
14. Prenatal screening for Down's syndrome with use of maternal serum markers. Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344 [TBL] [Abstract][Full Text] [Related]
15. [Ultrasound screening for Down's syndrome early in pregnancy: nuchal translucency thickness]. Müller MA; Pajkrt E; Bilardo CM Ned Tijdschr Geneeskd; 2002 Apr; 146(17):793-8. PubMed ID: 12014236 [TBL] [Abstract][Full Text] [Related]
16. Nuchal translucency measurement in first trimester Down syndrome screening. Scott A Issues Emerg Health Technol; 2007 Jun; (100):1-6. PubMed ID: 17595751 [TBL] [Abstract][Full Text] [Related]
17. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases. Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230 [TBL] [Abstract][Full Text] [Related]
18. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399 [TBL] [Abstract][Full Text] [Related]